[The economic evaluation of prostatic hyperthermia].
The aim of this study is to assess the hospital cost of treating Benign Prostatic Hyperplasia (BPH) by hyperthermia. The cost analysis was conducted simultaneously with a randomized clinical essay comparing hyperthermia to sham; the analysis was promoted by the Committee for Evaluation and Diffusion of Innovative Technologies (CEDIT) of the AP-HP. Cost components are: medical and paramedical staff salaries, supplies, overhead and capital costs. cost per session varies from FF 1200 to FF 5300; cost per treatment varies from FF 2500 to FF 9700 depending upon the equipment used. For comparison, annual drug treatment of BPH varies from FF 2600 to FF 2900. important variation in the treatment cost of BPH by hyperthermia is observed depending on the equipment used. Clinical data do not demonstrate improved efficacy with the costlier hyperthermia treatments. Drug treatment seems to be more cost effective than hyperthermia for BPH treatment.